Analyst Gregory Renza works at RBC and is focused on the Healthcare sector with 195 price targets and ratings documented since 2017 spanning on 17 stocks. Analyst's average stock valuation to be materialised ratio is 46.77% with an average time for price targets to be met of 117.88 days.
Most recent stock forecast was given on XNCR, Xencor, Inc at 08-Nov-2022.
Gregory Renza best performing recommendations are on INO (INOVIO PHARMACEUTICALS, INC).
The best stock recommendation documented was for INO (INOVIO PHARMACEUTICALS, INC) at 11/16/2020. The price target of $12 was fulfilled within 1 day with a profit of $0.85 (6.61%) receiving and performance score of 66.15.
Average potential price target upside